Dr. Michael Shapira, MD shares an early vaccine for myeloma and his work to raise the age ceiling for allo and auto transplants

Learn about all myeloma happenings on the new Myeloma Crowd site: the first comprehensive site for myeloma patients and caregivers. Dr. Michael Shapira, MD Haddassah Medical Center Interview date: April 18, 2014 Summary Dr. Shapira shares work done to test a myeloma vaccine from Vaxil called ImMucin that targets the MUC1 oncoprotein, found in about 70% of myeloma patients. This vaccine was used in an early clinical trial to test safety, but the study results look promising, even when used without other therapies. He also describes his work to increase the upper age limit effectively for transplantation including autologous and allogenic and how he has been able to reduce graft vs. host side effects of allogeneic transplant with multiple strategies. The live mPatient Myeloma Radio podcast with Dr. Michael Shapira

Learn about all myeloma happenings on the new Myeloma Crowd site: the first comprehensive site for myeloma patients and caregivers. Dr. Michael Shapira, MD Haddassah Medical Center Interview date: April 18, 2014 Summary Dr. Shapira shares work done to test a myeloma vaccine from Vaxil called ImMucin that targets the MUC1 oncoprotein, found in about 70% of myeloma patients. This vaccine was used in an early clinical trial to test safety, but the study results look promising, even when used without other therapies. He also describes his work to increase the upper age limit effectively for transplantation including autologous and allogenic and how he has been able to reduce graft vs. host side effects of allogeneic transplant with multiple strategies. The live mPatient Myeloma Radio podcast with Dr. Michael Shapira